
© 2024 Edison Investment Research
Realtime | Geld | Brief | Zeit |
---|---|---|---|
6,920 | 7,080 | 19:07 | |
6,950 | 7,010 | 18:48 |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
29.01. | OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy | OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy Nantes and Paris - France, January 29, 2025 - 6:00pm CET - OSE... ► Artikel lesen | |
28.01. | OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO | ||
13.01. | OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer | OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer NANTES, France, January 13, 2025 - 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today... ► Artikel lesen | |
18.12.24 | OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Results in Ulcerative Colitis at 20th Congress of ECCO | ||
11.12.24 | OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi | OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi® ARTEMIA: Clinical trial protocol approved globally. Most countries and sites activated... ► Artikel lesen |